DE3853779D1 - Hiv-1 neutralisierende monoklonale antikörper. - Google Patents

Hiv-1 neutralisierende monoklonale antikörper.

Info

Publication number
DE3853779D1
DE3853779D1 DE3853779T DE3853779T DE3853779D1 DE 3853779 D1 DE3853779 D1 DE 3853779D1 DE 3853779 T DE3853779 T DE 3853779T DE 3853779 T DE3853779 T DE 3853779T DE 3853779 D1 DE3853779 D1 DE 3853779D1
Authority
DE
Germany
Prior art keywords
hiv
antibodies
monoclonal antibodies
neutralizing monoclonal
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE3853779T
Other languages
English (en)
Other versions
DE3853779T2 (de
Inventor
Tse Chang
Sek Fung
Cecily Sun
Bill Sun
Nancy Chang
Ruey Liou
Edward Rosen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baylor College of Medicine
Tanox Inc
Original Assignee
Baylor College of Medicine
Tanox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College of Medicine, Tanox Inc filed Critical Baylor College of Medicine
Publication of DE3853779D1 publication Critical patent/DE3853779D1/de
Application granted granted Critical
Publication of DE3853779T2 publication Critical patent/DE3853779T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE3853779T 1987-05-29 1988-05-27 Hiv-1 neutralisierende monoklonale antikörper. Expired - Fee Related DE3853779T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5744587A 1987-05-29 1987-05-29
US13786187A 1987-12-24 1987-12-24
US19776688A 1988-05-23 1988-05-23
PCT/US1988/001797 WO1988009181A2 (en) 1987-05-29 1988-05-27 Monoclonal antibodies neutralizing hiv-1

Publications (2)

Publication Number Publication Date
DE3853779D1 true DE3853779D1 (de) 1995-06-14
DE3853779T2 DE3853779T2 (de) 1995-09-07

Family

ID=27369250

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3853779T Expired - Fee Related DE3853779T2 (de) 1987-05-29 1988-05-27 Hiv-1 neutralisierende monoklonale antikörper.

Country Status (6)

Country Link
EP (1) EP0366718B1 (de)
JP (1) JP2520464B2 (de)
AT (1) ATE122237T1 (de)
CA (1) CA1339857C (de)
DE (1) DE3853779T2 (de)
WO (1) WO1988009181A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
US5591829A (en) * 1987-05-29 1997-01-07 Matsushita; Shuzo Antibodies modified with toxic substance
US5854400A (en) * 1987-05-29 1998-12-29 Tanox, Inc. Monoclonal antibodies which neutralize HIV-1 infection
EP0400076B1 (de) * 1988-01-26 1996-05-15 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Synthetisches antigen zum bewirken einer anti-hiv-reaktion
JP2646007B2 (ja) * 1988-01-30 1997-08-25 財団法人 化学及血清療法研究所 抗ｈｉｖ抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗ｈｉｖキメラ抗体ならびにその製法
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
US5763160A (en) * 1988-02-12 1998-06-09 United Biomedical, Inc. Synthetic peptides and process of using same for the detection of antibodies to human immunodeficiency virus (HIV) gp120 envelope protein, diagnosis of AIDS and pre-AIDS conditions and as vaccines
US5562905A (en) * 1988-04-26 1996-10-08 E. I. Du Pont De Nemours And Company Human immunodeficiency virus (hiv) env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals
EP0339504A3 (de) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Menschliches immunoinsuffizientes Virus (HIV) env-codiertes Peptid, welches im Stande ist, die HIV hemmenden Antikörper bei Säugetieren hervorzurufen
EP0370090B1 (de) * 1988-05-13 1996-07-10 University Patents, Inc. Von gemeinsamen sequenzen von antigenen und antiidiotypischen antikörpern oder von antikörpern mit spezifizität für die zellulären rezeptoren der antigene abgeleitete immunogene und biologisch aktive peptide
EP0436634A1 (de) * 1988-10-03 1991-07-17 Repligen Corporation Hiv-proteine und peptide und deren verwendung zur diagnose, prophylaxe und therapie von aids
EP0365209A3 (de) * 1988-10-17 1990-07-25 Becton, Dickinson and Company Aminosäuresequenz des Anti-leu 3a
IL89491A0 (en) * 1988-11-17 1989-09-10 Hybritech Inc Bifunctional chimeric antibodies
WO1990012868A1 (en) * 1989-04-25 1990-11-01 Tanox Biosystems, Inc. Antibodies specific for cd4-binding domain of hiv
JP2782232B2 (ja) * 1989-05-29 1998-07-30 日東電工株式会社 プロテアーゼ阻害剤
AU6036690A (en) * 1989-06-05 1991-01-07 Helen F. Carson Human monoclonal antibodies to hiv-1mn gp 120
CA2022959C (en) * 1989-08-10 2001-03-20 Hiroaki Maeda Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
CA1339415C (en) * 1989-08-24 1997-09-02 Milton David Goldenberg Detection and treatment of infections with immunoconjugates
US5332567A (en) * 1989-08-24 1994-07-26 Immunomedics Detection and treatment of infections with immunoconjugates
EP0453554A4 (en) * 1989-11-13 1993-02-17 Xoma Corporation Chimeric mouse human antibodies with specificity to hiv antigens
JPH03206888A (ja) * 1989-11-13 1991-09-10 Green Cross Corp:The Ｈｉｖ抗原に対し特異性を持つマウス―ヒトキメラ抗体
WO1991010722A2 (en) * 1989-12-27 1991-07-25 Centocor, Inc. Chimeric immunoglobulin for cd4 receptors
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
SE9000333D0 (sv) * 1990-01-31 1990-01-31 Britta Wahren Monoklonal antikropp
US5914109A (en) * 1990-06-15 1999-06-22 New York University Heterohybridomas producing human monoclonal antibodies to HIV-1
JP2989862B2 (ja) * 1990-07-02 1999-12-13 財団法人化学及血清療法研究所 モノクローナル抗体
US5712373A (en) * 1990-07-02 1998-01-27 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute HIV monoclonal antibody specific for the HTLV-IIImn gp120 envelope glycoprotein
CA2091253A1 (en) * 1990-09-28 1992-03-29 Franco Celada Method for inhibiting the infectivity of human immunodeficiency virus
EP0554401A4 (en) * 1990-10-26 1996-10-30 New York Health Res Inst Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
WO1992008983A1 (en) * 1990-11-19 1992-05-29 Queen's University At Kingston Hiv marker/aids vaccine
WO1994004574A1 (en) * 1991-08-22 1994-03-03 Nissin Shokuhin Kabushiki Kaisha Hiv immunotherapeutics
KR100251823B1 (ko) * 1991-08-22 2000-04-15 안도 고끼 사람 면역 결핍 바이러스(hiv) 감염의 면역치료용 모노클로날 항체
JPH0748276A (ja) * 1992-03-26 1995-02-21 Inmeru:Kk Ｈｉｖ感染症予防ワクチンおよびその製造法
RU94045907A (ru) * 1992-04-01 1996-11-10 Мерк Энд Ко. Вич-антитела человека или их фрагменты, экспрессионные кассеты, клетки-хозяева, фармацевтические композиции, способ защиты
GB9217124D0 (en) * 1992-08-13 1992-09-23 Antisoma Ltd Medical treatment
ATE256751T1 (de) * 1993-03-11 2004-01-15 Chemo Sero Therapeut Res Inst Monoklonaler anti-hiv antikörper
US5618922A (en) * 1994-07-25 1997-04-08 Nissin Shokuhin Kabushiki Kaisha NM03 antibody materials and methods
AU6518698A (en) * 1997-03-28 1998-10-22 Seikagaku Corporation Novel anti-hiv complexes and medicinal compositions
DE19809785C2 (de) * 1998-03-08 2000-02-10 Wolfgang Bergter Radioimmunpharmakon zur Behandlung der HIV-1-Infektion
US6472191B1 (en) 1998-12-03 2002-10-29 Canon Kabushiki Kaisha Dna fragment carrying toluene monooxygenase gene, recombinant plasmid, transformed microorganism, method for degrading chlorinated aliphatic hydrocarbon compounds and aromatic compounds, and method for environmental remediation
EP2016173A4 (de) * 2006-05-15 2010-06-09 Immunomedics Inc Verfahren und zusammensetzungen zur behandlung menschlicher immundefekt-virusinfektionen mit konjugierten antikörpern oder antikörperfragmenten
CA2982376A1 (en) 2015-05-28 2016-12-01 Immunomedics, Inc. T20 constructs for anti-hiv (human immunodeficiency virus) therapy and/or vaccines

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5843926A (ja) * 1981-09-08 1983-03-14 Suntory Ltd 選択性制癌剤
FR2571968B1 (fr) * 1984-10-18 1989-03-17 Pasteur Institut Virus purifie des lymphadenopathies et du syndrome d'immuno-depression acquise et antigenes d'enveloppe de ce virus, procede d'obtention de ce virus et de ces antigenes d'enveloppe de ce virus, applications de ce virus ou de ces antigenes a la preparation de compositions immunogenes ou pour le diagnostic des susdites affections.
JPS6147500A (ja) * 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
ATE250083T1 (de) * 1984-10-18 2003-10-15 Pasteur Institut Lav-antigene und -peptide
JP2702911B2 (ja) * 1985-09-11 1998-01-26 ユナイテツド・バイオメデイカル・インコ−ポレ−テツド 合成ペプチド、並びにそれを用いたエイズおよびプリ・エイズの検出方法
EP0245362B1 (de) * 1985-10-24 1994-06-29 Ronald C. Kennedy Synthetische peptide und deren verwendung zur diagnose und impfung für aids und arc
NZ221440A (en) * 1986-08-20 1991-11-26 Genetic Systems Corp Composition containing monoclonal antibodies/peptides useful in treating and diagnosing hiv infections

Also Published As

Publication number Publication date
WO1988009181A3 (en) 1989-02-09
WO1988009181A2 (en) 1988-12-01
JP2520464B2 (ja) 1996-07-31
EP0366718A1 (de) 1990-05-09
CA1339857C (en) 1998-05-05
ATE122237T1 (de) 1995-05-15
JPH03504556A (ja) 1991-10-09
DE3853779T2 (de) 1995-09-07
EP0366718B1 (de) 1995-05-10

Similar Documents

Publication Publication Date Title
ATE122237T1 (de) Hiv-1 neutralisierende monoklonale antikörper.
AU8083594A (en) Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
DE3850542T2 (de) Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen.
EP0651818A4 (de) Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4-rezeptorbindung.
AU563356B2 (en) Conjugate of enzyme and antibody
ES2010727A6 (es) Metodo para producir lineas celulares que producen anticuerpos monoclonales reactivos frente a determinantes antigenicos de gp110 o de p25 de hiv.
IL91007A0 (en) Synthetic vaccine against aids virus
ES2194015T3 (es) Anticuerpos monoclonales humanos neutralizantes del virus de inmunodeficiencia humana.
IL118626A0 (en) Anti HBV antibody
DE3855134D1 (de) Monoklonale menschliche antikörper gegen hiv-i
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
CA2170034A1 (en) Recombinant humanized anti-human immunodeficiency virus antibody
DE69227500D1 (de) In der Therapie von einer HIV-1-Infektion verwendbare monoklonale Antikörper
WO1997046697A3 (en) Antibodies against a complex of cd4 and a chemokine receptor domain, and their use against hiv infections
ES468363A1 (es) Proceso para la fabricacion de un preparado destinado al tra-tamiento de herpes-zoster.
AU8010791A (en) Hiv monoclonal antibody
DE3854267D1 (de) HIV-spezifische monoklonale Antikörper und Hybridome zu ihrer Herstellung.
WO1993001820A3 (en) Inhibition of non-cd4 mediated hiv infection
DE3874606D1 (de) Behandlung von viraler infektion.
CA2160696A1 (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus
ES2060162T3 (es) Utilizacion de los anticuerpos monoclonales anti-b2 microglobulina.
AU5657590A (en) Beta-hydroxamate d-aspartic acid for treatment of viral infections and tumours
DE69619123D1 (de) Hämoregulatorische verbindungen
EP0835124A4 (de) Serumzusammensetzungen zur hemmung von retroviren und tumorwachstum
RU94024562A (ru) Антитело, полинуклеотид, клетка, способ получения антитела

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee